This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Pacira Surges 66.8% in Six Months: How Should You Play the Stock?
by Ekta Bagri
PCRX has put up a strong performance in six months with shares rallying 66.8%. However, its sole dependence on Exparel for growth is a concern. We advise investors to wait for now.
DVAXNegative Net Change GILDNegative Net Change PCRXNegative Net Change
biotechnology biotechs medical pharmaceuticals
5 High ROE Stocks to Buy as Markets Dip Despite Rate Cut Hopes
by Supriyo Bose
MPLX, LDOS, JAZZ, FTNT and PPC are some of the stocks with high ROE to profit from as markets falter on tariff concerns.
JAZZNegative Net Change PPCNegative Net Change FTNTNegative Net Change MPLXPositive Net Change LDOSNegative Net Change
aerospace biofuels biotechnology consumer-discretionary tech-stocks
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics
by Zacks Equity Research
Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics are included in this Analyst Blog.
GILDNegative Net Change INCYPositive Net Change SRPTNegative Net Change VTVTPositive Net Change
biotechnology
GILD Stock Down on Report of Cut in HIV Prevention Spending
by Zacks Equity Research
Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash funding for HIV prevention in the country.
GSKPositive Net Change PFENegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
ENZ Stock Down Following Q2 Earnings, Revenues Decline Y/Y
by Zacks Equity Research
Enzo Biochem revenues decline in second-quarter fiscal 2025. Cost cuts improve margins, but NYSE compliance issues and market slowdown persist.
biotechnology biotechs earnings medical
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More
by Zacks Equity Research
SRPT and INCY are in the spotlight this week following a report of an adverse event and study data, respectively.
GILDNegative Net Change INCYPositive Net Change SRPTNegative Net Change VTVTPositive Net Change
biotechnology biotechs medical pharmaceuticals
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
by Zacks Equity Research
Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.
DVAXNegative Net Change GILDNegative Net Change ARVNNegative Net Change IMVTNegative Net Change
biotechnology biotechs medical pharmaceuticals
5 Undervalued ETFs to Ride on Powell's Market Optimism
by Sweta Killa
The Fed lifted market confidence amid economic uncertainty, leading to a rally in the U.S. stock market.
SPYPositive Net Change KBENegative Net Change XOPNegative Net Change SPYDNegative Net Change SPVUPositive Net Change IBBQPositive Net Change
biotechnology energy etfs finance
Novartis Reports Updated Positive Data From Phase III SMA Program
by Zacks Equity Research
NVS reports new safety and efficacy data from the phase III program for its investigational OAV101 IT gene therapy for SMA patients.
NVSPositive Net Change RHHBYPositive Net Change DVAXNegative Net Change GILDNegative Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
HRMY Down 10.8% in Six Months: How Should You Play the Stock?
by Ekta Bagri
A recent regulatory setback has hit Harmony Biosciences stock. We recommend prospective investors to wait for a while before turning positive.
JAZZNegative Net Change AXSMNegative Net Change HRMYNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review
by Zacks Equity Research
Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.
RDYNegative Net Change AMGNPositive Net Change GILDNegative Net Change ALVONegative Net Change
biotechnology biotechs medical pharmaceuticals
NVIDIA GTC: 7 Big Takeaways from Jensen
by Kevin Cook
The Wizard of AI never fails to wow the crowd and Tuesday's keynote was no exception
NVDAPositive Net Change
artificial-intelligence autonomous-vehicles biotechnology cloud-computing dna-sequencing robotics self-driving-cars
Buy 3 U.S. Giants Flying High Year to Date Defying Severe Volatility
by Nalak Das
Three U.S. bigwigs flying high year to date with more upside are GILD, GE and PGR.
GEPositive Net Change GILDNegative Net Change PGRPositive Net Change
aerospace biotechnology insurance
INCY Stock Down on Disappointing Skin Disease Study Data
by Zacks Equity Research
Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.
GSKPositive Net Change BMRNNegative Net Change GILDNegative Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock?
by Ahan Chakraborty
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
RHHBYPositive Net Change MRKPositive Net Change BAYRYNegative Net Change RXRXNegative Net Change
artificial-intelligence biotechnology biotechs cancer medical oncology-screening pharmaceuticals
Bull of the Day: NVIDIA (NVDA)
by Kevin Cook
Today Jensen will unveil more wonders from his magic shop at 10am PDT. Learn about DIGITS here first!
NVDAPositive Net Change
artificial-intelligence automation autonomous-vehicles biotechnology cloud-computing genomics self-driving-cars semiconductor
GILD Stock Trading Close to Its 52-Week High: Should You Buy or Sell?
by Ekta Bagri
Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the stock to investors.
GSKPositive Net Change MRKPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Astronics Corporation (ATRO)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
ATRONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies
by Zacks Equity Research
AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or immune-mediated diseases.
AZNPositive Net Change BMRNNegative Net Change GILDNegative Net Change CORTNegative Net Change
biotechnology biotechs cell-therapy immuno-therapy medical oncology-screening pharmaceuticals
Will ADMA Biologics Stock Continue Its Momentum in 2025?
by Zacks Equity Research
ADMA continues to maintain momentum in 2025 after its stupendous performance in 2024. Strong demand for Asceniv should fuel growth.
GRFSPositive Net Change ADMANegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?
by Zacks Equity Research
ALNY stock soars 62% in a year, driven by increasing Amvuttra and Givlaari sales. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
REGNPositive Net Change ALNYPositive Net Change NVSPositive Net Change RHHBYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Follow the Leader: 2 Biopharma Stocks Showing Relative Strength in 2025
by Bryan Hayes
Despite a correction to begin the year, there are a few pockets of the market that are working.
GILDNegative Net Change JAZZNegative Net Change
biotechnology biotechs cancer cell-therapy earnings immuno-therapy investing medical oncology-screening pharmaceuticals
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More
by Ekta Bagri
TSVT and PTGX are in the spotlight this week following an acquisition agreement and study data, respectively.
BMYNegative Net Change GILDNegative Net Change PTGXNegative Net Change ARVNNegative Net Change
biotechnology biotechs medical pharmaceuticals
GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive
by Zacks Equity Research
Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the drug.
GSKPositive Net Change PFENegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
ARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study
by Zacks Equity Research
Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.
AZNPositive Net Change PFENegative Net Change GILDNegative Net Change ARVNNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals